Video proceedings from the fifth in a series of 6 integrated
symposia held at the 2019 ONS Annual Congress. Featuring
perspectives from Dr Erika Hamilton, Ms Elizabeth O’Reilly, Dr Hope
S Rugo and Ms Gretchen Santos:
Introduction (00:00)
Program overview: Dr Love
HER2-Positive Localized and Metastatic Breast Cancer
(BC) (2:16)
Case (Ms O’Reilly): A woman in her late 40s with ER-positive,
HER2-positive Stage IIIB inflammatory BC who received neoadjuvant
treatment, had significant residual disease at surgery and began
adjuvant T-DM1 (9:04)
Case (Ms Santos): A woman in her early 60s with ER-negative,
HER2-positive BC who began 1 year of adjuvant
trastuzumab/pertuzumab after mastectomy but was switched to T-DM1
(12:31)
Case (Ms Santos): A woman in her early 40s with ER-positive,
HER2-positive BC who received postadjuvant neratinib on the CONTROL
study (38:38)
Case (Ms O’Reilly): A woman in her early 60s initially
diagnosed with ER-positive, HER2-negative BC presents with
ER-positive, HER2-positive metastatic disease to the bone, liver
and brain (43:41)
Case (Ms Santos): A premenopausal woman in her early 50s with
widespread ER/PR-positive, HER2-negative metastatic BC to the bone
who underwent ovarian ablation and received palbociclib/letrozole
(1:5:38)
Case (Ms O’Reilly): A woman in her early 50s with ER-positive
metastatic BC who received multiple lines of systemic treatment,
including abemaciclib monotherapy (1:15:53)
Triple-Negative Metastatic BC (1:31:31)
Case (Ms Santos): A woman in her mid-30s with metastatic
triple-negative BC who experienced a good response to pembrolizumab
(1:37:46)
Featuring the video recorded proceedings of events held in conjunction with important scientific symposia, live webcasts and closed meetings featuring the perspectives of renowned clinical investigators, these videos provide an overview of important advances in the management of a number of solid tumors and hematologic cancers.